CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Seeking Alpha
Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Early enrollment completion in the phase 3 PIVOT-006 trial for IR-NMIBC accelerates topline data to 1H 2026, positioning the company for a potential first FDA approval in this segment. With $680.3M in cash, the company is funded into 1H 2028, supporting ongoing clinical and regulatory milestones; a significant rise in stock price might warrant management to raise cash earlier than expected. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » FabrikaCr/iStock via Getty Images The last time I spoke about CG Oncology CGON ) it was with respect to a Seeking Alpha article entitled " CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene ". With respect to this article, I More on my IG service This
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? [Yahoo! Finance]Yahoo! Finance
- CG Oncology (NASDAQ:CGON) was given a new $93.00 price target on by analysts at Morgan Stanley.MarketBeat
- CG Oncology (NASDAQ:CGON) was given a new $66.00 price target on by analysts at Truist Financial Corporation.MarketBeat
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 1/13/26 - Form 8-K
- 1/13/26 - Form 424B5
- 1/13/26 - Form 4
- CGON's page on the SEC website